Human Intracranial Biomarkers for State-Dependent Neuromodulation in Epilepsy
Part of Personalized Neuromodulation in Epilepsy: Closing the Loop
Details
- Date
- Friday, January 22, 2027
- Time
- 4:50 PM – 5:05 PM
- Session type
- Concurrent Session
- Schedule
- See this day
About
Personalized neuromodulation holds promise for improving epilepsy treatment, yet several fundamental questions remain unresolved: (1) how to detect and define brain states that trigger intervention, (2) what stimulation parameters should be used, and (3) where stimulation should be delivered. These challenges have sparked significant interest across the field, with multiple groups pursuing diverse AI driven, network driven, and biomarker driven approaches to optimize neuromodulation. This session seeks to "close the loop" on closed-loop neuromodulation in epilepsy by bringing together leaders in the field to discuss emerging strategies for state detection, stimulation optimization, and network targeting.
Presenters
-
Sydney Cash, MD, PhD
Professor
Mass General Brigham / Harvard Medical School · Boston, Massachusetts
Dr. Sydney Cash is Professor of Neurology at Harvard Medical School and epileptologist at Massachusetts General / Birgham and Women's Hospital. Dr. Cash received his BS in Biology from Yale before going on to pursue an MD/PhD at Columbia University. Following residency in Neurology at MGH/BWH, Dr. Cash completed a fellowship in epilepsy and neurophysiology at Massachusetts General Hospital. Dr. Cash's research focuses on understanding the mechanisms underlying both normal and pathological cortical activity and developing novel neuroprosthetic approaches for treating a wide variety of neurological problems. This work, funded by NIH, DOD, NSF and foundation grants, has melded issues spanning basic neuroscientific questions of the physiology that underlie normal oscillatory activity, sleep and cognition, to issues surrounding how the brain transitions from one state to another including from normal activity to seizure activity and how seizures can be localized and treated. Particularly relevant to the symposium at NANS, his group has been exploring the physiological biomarkers that may be useful in detrmining which patients might benefit from RNS and, if so, where electrodes should be placed and what stimulation paradigms are likely to prove the most efficacious for controlling seizures and improving patient outcomes.